Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 199.07

-3.4%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (10941)	11/10/1997 2:17:00 PM
From: Andrew H	Read Replies (2) of 32384

>>By the time Tragretin is approved, LGND should have advanced interim clinical data from Europe as well as North America (for type II diabetes). With FDA reform in place, they will be able to show the interim data to physicians and begin off label sales. Likewise, the drug is in Phase II/III lung cancer trials which is a much bigger market and that data should come out this quarter. I expect off-label Targretin sales to be significant.<< It would seem pretty certain to me that Targretin would receive fast track consideration. I think you are correct that Targretin will be a big seller for diabetes although it may take a while. Doctors may hesitate to throw another drug into the rezulin liver problem equation before extensive testing is done. Still, targretin has been around for quite a while now and safety and side effect data should be considerable.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next